About 15,000 people are diagnosed with soft tissue sarcomas every year in the United States. About 4,800 of them will die. Soft tissue sarcomas are cancers that originate in the tissues connecting, supporting, and surrounding other body structures, such as muscle, fat, blood vessels, nerves, tendons, and the lining of joints. Often the chemotherapeutic agents used to treat soft tissue sarcomas are as devastating to the patient as the disease. Though oncologists often measure success as simply days of survival regardless of the quality of those days, Janssen was launching the first new product in many years for that was proven to prolong progression-free survival, with potentially less cumulative toxicity.